betaxolol has been researched along with penbutolol in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Biamino, G; Schröder, R | 1 |
| Bengtsson, HJ; Hjorth, S; Milano, S | 1 |
2 review(s) available for betaxolol and penbutolol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
What is the real pharmacological rationale for beta-receptor blocking agents?
Topics: Adrenergic beta-Antagonists; Betaxolol; Coronary Disease; Heart Rate; Humans; Myocardial Contraction; Myocardial Infarction; Myocardium; Oxygen Consumption; Penbutolol; Physical Exertion; Propanolamines; Propranolol | 1983 |
3 other study(ies) available for betaxolol and penbutolol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Raphe 5-HT1A autoreceptors, but not postsynaptic 5-HT1A receptors or beta-adrenoceptors, restrain the citalopram-induced increase in extracellular 5-hydroxytryptamine in vivo.
Topics: Adrenergic beta-Antagonists; Animals; Betaxolol; Citalopram; Extracellular Space; Hippocampus; Male; Microdialysis; Penbutolol; Piperazines; Propanolamines; Pyridines; Raphe Nuclei; Rats; Rats, Sprague-Dawley; Receptors, Adrenergic, beta; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Antagonists | 1996 |